Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

3.3K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
3.3K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.0K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.0K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

2.1K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.1K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

682
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
682
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

4.0K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
4.0K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

5.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of once-daily ICS/LAMA/LABA triple therapy versus ICS/LABA on respiratory symptoms (E-RS: Asthma): Analysis of the phase IIIA CAPTAIN trial.

The journal of allergy and clinical immunology. Global·2026
Same author

Clinical phenotyping of asthma patients with elevated sputum eosinophils and low blood eosinophils: a post-hoc analysis of the multicentre ATLANTIS cohort.

EBioMedicine·2026
Same author

Digital inhaler data in routine asthma care: defining a minimal dataset for clinical decision support (AURORA): a modified delphi study.

NPJ primary care respiratory medicine·2026
Same author

Fentanyl or Morphine for Persistent Dyspnea in COPD: a multicenter randomised cross-over trial.

The European respiratory journal·2026
Same author

Hair analysis of formoterol as a novel tool to assess long-term inhalation medication adherence: Data from the TRICOLON trial.

British journal of clinical pharmacology·2026
Same author

Association of blood eosinophils and exhaled nitric oxide with exacerbations in patients with asthma, COPD and asthma+COPD: the NOVELTY study.

Thorax·2026

Related Experiment Video

Updated: Mar 11, 2026

Author Spotlight: Integrating Alveolar-Capillary Reserve Measurements in Exercise Adaptation and Therapeutic Strategies
08:44

Author Spotlight: Integrating Alveolar-Capillary Reserve Measurements in Exercise Adaptation and Therapeutic Strategies

Published on: February 2, 2024

1.4K

Stable State Proadrenomedullin Level in COPD Patients: A Validation Study.

Maaike Zuur-Telgen1,2, Paul VanderValk1, Job van der Palen1,3

  • 1a Department of Pulmonary Medicine , Medisch Spectrum Twente , Enschede , the Netherlands.

COPD
|November 24, 2016
PubMed
Summary

Mid-regional pro-adrenomedullin (MR-proADM) effectively predicts mortality in stable COPD patients. Elevated MR-proADM levels in stable COPD indicate a significantly higher risk of death, validating its use as a prognostic marker.

Keywords:
BiomarkersCOPDmortalityvalidation study

More Related Videos

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults
06:11

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults

Published on: February 9, 2022

6.5K
A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

24.4K

Related Experiment Videos

Last Updated: Mar 11, 2026

Author Spotlight: Integrating Alveolar-Capillary Reserve Measurements in Exercise Adaptation and Therapeutic Strategies
08:44

Author Spotlight: Integrating Alveolar-Capillary Reserve Measurements in Exercise Adaptation and Therapeutic Strategies

Published on: February 2, 2024

1.4K
Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults
06:11

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults

Published on: February 9, 2022

6.5K
A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

24.4K

Area of Science:

  • Biomarkers in Respiratory Diseases
  • Prognostic Indicators in Chronic Illness
  • Clinical Validation Studies

Background:

  • Mid-regional pro-adrenomedullin (MR-proADM) is a potential mortality predictor in stable COPD.
  • Previous studies suggested specific cut-off values for MR-proADM in COPD prognosis.
  • External validation is crucial to confirm the reliability of these cut-off values.

Purpose of the Study:

  • To externally validate previously identified MR-proADM cut-off values in a stable COPD cohort.
  • To assess the predictive value of MR-proADM for mortality in stable COPD patients and during acute exacerbations.
  • To compare the prognostic performance of MR-proADM at different cut-off points.

Main Methods:

  • Analysis of 545 COPD patients from the COMIC cohort study.
  • Blood samples collected during stable state (n=490) and AECOPD hospitalization (n=101).
  • Comparison of mortality rates based on MR-proADM levels against established cut-off values (0.71, 0.75 nmol/L for stable; 0.79, 0.84 nmol/L for AECOPD).

Main Results:

  • Patients with stable MR-proADM levels above 0.75 nmol/L had a 2-fold higher mortality risk (95% CI: 1.20-3.41).
  • A cut-off of 0.71 nmol/L showed a borderline significant increase in mortality risk (1.67, 95% CI: 0.98-2.85).
  • MR-proADM levels during AECOPD hospitalization were not predictive of mortality in this cohort.

Conclusions:

  • MR-proADM measured in stable state is a powerful and validated predictor of mortality in COPD patients.
  • The validated cut-off of 0.75 nmol/L for stable COPD provides significant prognostic information.
  • MR-proADM is not a reliable mortality predictor during acute exacerbations of COPD.